SCHEMBL10052247

SCHEMBL10052247

O=C1C=C(NP)C(=O)c2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.61
▸ RAB9A P51151 6/20 0.61
▸ LMNA P02545 5/20 0.61
▸ MAPK1 P28482 4/20 0.61
▸ SMN1; SMN2 Q16637 4/20 0.61
▸ NPC1 O15118 4/20 0.61
▸ ALDH1A1 P00352 3/20 0.61
▸ L3MBTL1 Q9Y468 3/20 0.61
▸ HTT P42858 3/20 0.61
▸ NFKB1 P19838 1/20 0.61
▸ NFKB2 Q00653 1/20 0.61
▸ RELA Q04206 1/20 0.61
▸ BLM P54132 5/20 0.54
▸ MAOA P21397 3/20 0.54
▸ MAOB P27338 2/20 0.54
▸ HKDC1 Q2TB90 2/20 0.54
▸ TDP2 O95551 2/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ EPHB2 P29323 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29633340 0.79 MAPT (0.61) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL3272791 0.79 MAPT (0.61) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL4540326 0.79 MAPT (0.61) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL30587657 0.76 MALT1 (0.73) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL7913507 0.76 MAPT (0.58) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL15690493 0.76 MALT1 (0.73) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL754259 0.76 MAPT (1.00) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL29633257 0.76 MAPT (1.00) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL4541864 0.75 MAOA (0.63) MAPTRAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL15630316 0.75 MAOA (0.63) MAPTRAB9ALMNAMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9180222-B2 Polymeric tissue sealant KUROS BIOSURGERY AG (CH) 2015-11-10 — — US disclosed
US-20150133579-A1 Polymeric Tissue Sealant KUROS BIOSURGERY AG (CH) 2015-05-14 — — US disclosed
US-8961947-B2 Polymeric tissue sealant KUROS BIOSURGERY AG (CH) 2015-02-24 — — US disclosed
US-20140343324-A1 SYNTHETIC MATRIX FOR CONTROLLED CELL INGROWTH AND TISSUE REGENERATION Eidgenossische Technische Hochschule Zürich (CH) 2014-11-20 — — US disclosed
US-20130243878-A1 BIOMATERIALS FOR DELIVERY OF BLOOD EXTRACTS AND METHODS OF USING SAME MOSAIC BIOSCIENCES, INC. (US) 2013-09-19 — — US disclosed
EP-2537539-A1 Polymeric Tissue Sealant Kuros Biosurgery AG (CH) 2012-12-26 — — EP disclosed
US-8282912-B2 Compositions for tissue augmentation Kuros Biosurgery, AG (CH) 2012-10-09 — — US disclosed
EP-2136850-B1 POLYMERIC TISSUE SEALANT KUROS BIOSURGERY AG (CH) 2012-02-01 — — EP disclosed
EP-1494730-B1 COMPOSITION FOR HARD TISSUE AUGMENTATION KUROS BIOSURGERY AG (CH) 2012-01-18 — — EP disclosed
US-8048407-B2 In situ gelling self-reactive materials for embolization VERNON BRENT 2011-11-01 — — US disclosed
US-7744912-B1 Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2010-06-29 — — US disclosed
US-7670605-B2 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2010-03-02 — — US disclosed
US-20100034769-A1 COMPOSITIONS FOR TISSUE AUGMENTATION Kuros Biosurgery, AG 2010-02-11 — — US disclosed
US-7575740-B2 Compositions for tissue augmentation KUROS BIOSURGERY AG (CH) 2009-08-18 — — US disclosed
US-20090098083-A1 CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS UNIVERSITAT ZURICH (CH) 2009-04-16 — — US disclosed
WO-2008125655-A1 POLYMERIC TISSUE SEALANT KUROS BIOSURGERY AG (CH) 2008-10-23 — — WO disclosed
US-20080253987-A1 Biomaterial from precursors pentaerythritol poly(ethylene glycol)ether tetra-sulfhydryl and an ethylene oxide-propylene oxide star polymer having ethylene diamine as the nucleus and acrylate end groups; containing biological fluids or gases; nonswelling, high mechanical strength, biocompatability KUROS BIOSURGERY AG 2008-10-16 — — US disclosed
US-7413739-B2 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2008-08-19 — — US disclosed
US-20070264227-A1 Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH 2007-11-15 — — US disclosed
US-7291673-B2 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds EIDGENOSSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) 2007-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343324-A1 SYNTHETIC MATRIX FOR CONTROLLED CELL INGROWTH AND TISSUE REGENERATION FGF2, EPCAM, FGF1 MAPT 4268/4885RAB9A 4505/4885LMNA 2087/4885
US-20130243878-A1 BIOMATERIALS FOR DELIVERY OF BLOOD EXTRACTS AND METHODS OF USING SAME PDGFA, PGF, MATR3 MAPT 1777/4885RAB9A 1818/4885LMNA 862/4885
US-20070264227-A1 Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration FGF2, EPCAM, FGF1 MAPT 4268/4885RAB9A 4505/4885LMNA 2087/4885
US-20080253987-A1 Biomaterial from precursors pentaerythritol poly(ethylene glycol)ether tetra-sulfhydryl and an ethylene oxide-propylene oxide star polymer having ethylene diamine as the nucleus and acrylate end groups; containing biological fluids or gases; nonswelling, high mechanical strength, biocompatability PAM, BMP6, PTGER1 MAPT 4335/4885RAB9A 4488/4885LMNA 2901/4885
US-20100034769-A1 COMPOSITIONS FOR TISSUE AUGMENTATION BMP2, BMX, PTMS MAPT 4051/4885RAB9A 1577/4885LMNA 2058/4885
US-20090098083-A1 CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS PAICS, COASY, LIPA MAPT 2886/4885RAB9A 3170/4885LMNA 1405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback